- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Endometrial Clear Cell Carcinoma.
Displaying page 1 of 2.
| EudraCT Number: 2019-002888-10 | Sponsor Protocol Number: SYD985.003 | Start Date*: 2020-03-25 | |||||||||||
| Sponsor Name:Byondis BV | |||||||||||||
| Full Title: A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who pr... | |||||||||||||
| Medical condition: Recurrent, Advanced or Metastatic Endometrial Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004403-31 | Sponsor Protocol Number: MITOEND-3 | Start Date*: 2022-03-24 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
| Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
| Medical condition: advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-000634-53 | Sponsor Protocol Number: AP23573-07-205(8669-007) | Start Date*: 2008-11-07 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., | ||||||||||||||||||
| Full Title: A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma | ||||||||||||||||||
| Medical condition: advanced endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) DE (Prematurely Ended) CZ (Completed) ES (Completed) IT (Completed) FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-000843-14 | Sponsor Protocol Number: GEICO_70-E | Start Date*: 2018-06-27 | |||||||||||||||||||||
| Sponsor Name:GEICO (Grupo Español de Investigación en Cáncer de Ovario) | |||||||||||||||||||||||
| Full Title: A phase II multicenter, open-label, single arm trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer | |||||||||||||||||||||||
| Medical condition: recurrent/metastatic endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2012-005546-38 | Sponsor Protocol Number: AEZS-108-050 | Start Date*: 2013-10-14 | ||||||||||||||||
| Sponsor Name:Aeterna Zentaris GmbH | ||||||||||||||||||
| Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer | ||||||||||||||||||
| Medical condition: Endometrial cancer, advanced, recurrent or metastatic | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-024396-12 | Sponsor Protocol Number: CBEZ235C2201 | Start Date*: 2011-06-13 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | |||||||||||||
| Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-002109-73 | Sponsor Protocol Number: NiCCC2013 | Start Date*: 2013-11-14 | ||||||||||||||||
| Sponsor Name:Greater Glasgow Health Board | ||||||||||||||||||
| Full Title: A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium | ||||||||||||||||||
| Medical condition: Recurrent clear cell carcinoma of the ovary or endometrium | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) FI (Prematurely Ended) NO (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-004917-33 | Sponsor Protocol Number: LUMCP06.031 | Start Date*: 2008-12-16 | |||||||||||||||||||||
| Sponsor Name:Leiden University Medical Centre | |||||||||||||||||||||||
| Full Title: A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma | |||||||||||||||||||||||
| Medical condition: Endometrial carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) AT (Ongoing) FR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2017-000300-26 | Sponsor Protocol Number: E7080-A001-111 | Start Date*: 2017-10-20 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal me... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) NO (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-023081-52 | Sponsor Protocol Number: ENGOT-EN2-DGCG | Start Date*: 2011-01-25 | ||||||||||||||||
| Sponsor Name:Danish Gynaecological Cancer Group (DGCG) | ||||||||||||||||||
| Full Title: A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. | ||||||||||||||||||
| Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DK (Completed) SE (Completed) BE (Completed) FI (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) IT (Completed) NL (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-000266-35 | Sponsor Protocol Number: CTKI258A2211 | Start Date*: 2012-03-21 | |||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||
| Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and... | |||||||||||||
| Medical condition: Advanced and/or metastatic endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003424-17 | Sponsor Protocol Number: MK3475-B21/ENGOT-en11/GOG-3053 | Start Date*: 2021-01-11 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endom... | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022015-19 | Sponsor Protocol Number: CBKM120C2201 | Start Date*: 2011-04-26 | |||||||||||
| Sponsor Name:Novartis Farmacéutica, S.A | |||||||||||||
| Full Title: Estudio de fase II, de una sola rama, de BKM120 administrado por vía oral como tratamiento de segunda línea en pacientes con carcinoma endometrial avanzado | |||||||||||||
| Medical condition: Mujeres adultas con carcinoma endometrial avanzado cuya enfermedad ha progresado durante o después del tratamiento antineoplásico de primera línea para la enfermedad avanzada. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003779-36 | Sponsor Protocol Number: ICR-CTSU/2018/10066 | Start Date*: 2019-10-11 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:The Institute of Cancer Research | ||||||||||||||||||||||||||||||||||||||
| Full Title: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma ... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-005394-37 | Sponsor Protocol Number: C31004 | Start Date*: 2016-08-31 | |||||||||||
| Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced... | |||||||||||||
| Medical condition: Advanced, Recurrent, or Persistent Endometrial Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) ES (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002079-93 | Sponsor Protocol Number: INCAGN1949-101 | Start Date*: 2017-07-17 | |||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Biosciences International Sàrl | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Part 1: advanced or metastatic solid tumors Part 2: advanced or metastatic adenocarcinoma of the endometrium, ovarian cancer, renal cell carcinoma (RCC), melanoma, and non–small cell lung cancer (... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-004060-40 | Sponsor Protocol Number: AGO15 | Start Date*: 2008-03-13 |
| Sponsor Name:Studienzentrale AGO Austria | ||
| Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer | ||
| Medical condition: primary advanced or recurrent/metastatic endometrial cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-016707-30 | Sponsor Protocol Number: XL147-201 | Start Date*: 2010-05-10 | |||||||||||
| Sponsor Name:Sanofi-aventis US Inc. | |||||||||||||
| Full Title: A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma | |||||||||||||
| Medical condition: The purpose of this study is to assess the efficacy and safety of XL147 in subjects with advanced or recurrent EC. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002429-37 | Sponsor Protocol Number: NSGO-EC-9501 Amendment 2 | Start Date*: 2004-11-17 |
| Sponsor Name:Nordic Society for Gynecologic Oncology | ||
| Full Title: A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2. | ||
| Medical condition: Endometrial cancer stage I-III radically operated with high-risk factors (high-grade and deep myometrial infiltration, or serous or clear cell histology) that will receive adjuvant treatment with r... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000339-21 | Sponsor Protocol Number: JK08.1.01 | Start Date*: 2022-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Salubris Biotherapeutics, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Unresectable Locally Advanced or Metastatic Cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
